Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acumen Pharmaceuticals Inc
(NQ:
ABOS
)
2.480
+0.050 (+2.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acumen Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
January 24, 2024
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population.
Via
InvestorPlace
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
November 17, 2023
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Via
Investor's Business Daily
Acumen Pharmaceuticals's Earnings Outlook
November 10, 2023
Via
Benzinga
Acumen Pharmaceuticals's Earnings: A Preview
August 07, 2023
Via
Benzinga
Why Shares of Acumen Pharmaceuticals Are Down Tuesday
July 18, 2023
The company announced a $100 million stock sale.
Via
The Motley Fool
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
November 13, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
Via
InvestorPlace
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 07, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
November 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
November 06, 2023
Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
November 02, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease
October 27, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
October 04, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
September 06, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
September 06, 2023
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...
Via
Benzinga
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
August 01, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
July 27, 2023
--News Direct--
Via
News Direct
Exposures
Product Safety
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
July 26, 2023
Although US stocks closed higher on Tuesday, there were a few notable insider trades.
Via
Benzinga
MarketBeat Week in Review – 7/17 - 7/21
July 22, 2023
Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
July 19, 2023
Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price?
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Acumen Announces Pricing of Upsized $130 Million Public Offering
July 18, 2023
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 18, 2023
Via
Benzinga
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 18, 2023
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.